Vanta Bioscience Limited (BOM:540729)
India · Delayed Price · Currency is INR 19.89
0.00 (0.00%)
At close: Feb 9, 2026
Vanta Bioscience Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 12.35 | 19.64 | 97.23 | 62.76 | 96.87 | 100.38 |
Other Revenue | - | - | - | - | 3.31 | 0.13 |
| 12.35 | 19.64 | 97.23 | 62.76 | 100.18 | 100.51 | |
Revenue Growth (YoY) | -73.02% | -79.81% | 54.93% | -37.35% | -0.33% | -28.94% |
Cost of Revenue | 16.88 | 15.38 | 8.49 | 9.91 | 8.16 | 9.29 |
Gross Profit | -4.53 | 4.25 | 88.74 | 52.85 | 92.03 | 91.23 |
Selling, General & Admin | 29.16 | 32.45 | 50.12 | 47.7 | 33.09 | 30.91 |
Other Operating Expenses | 8.74 | 14.37 | 25.33 | 29.09 | 20.95 | 20.19 |
Operating Expenses | 71.32 | 90.98 | 120.42 | 103.49 | 67.2 | 63.62 |
Operating Income | -75.84 | -86.72 | -31.68 | -50.64 | 24.83 | 27.61 |
Interest Expense | -27.57 | -40.19 | -57.23 | -56.05 | -23.47 | -20.61 |
Interest & Investment Income | 0.72 | 0.72 | 0.59 | 0.59 | 0.78 | - |
Currency Exchange Gain (Loss) | 0.35 | 0.35 | -0.16 | 0.09 | 0.15 | -0.53 |
Other Non Operating Income (Expenses) | -0.84 | -0.45 | -0.2 | 3.38 | - | -0.79 |
EBT Excluding Unusual Items | -103.19 | -126.29 | -88.69 | -102.63 | 2.28 | 5.68 |
Gain (Loss) on Sale of Assets | - | - | 0.42 | - | - | 0.22 |
Pretax Income | -103.19 | -126.29 | -88.27 | -102.63 | 2.28 | 5.89 |
Income Tax Expense | 6.6 | 6.61 | -2.2 | 1.82 | 0.94 | 1.41 |
Earnings From Continuing Operations | -109.79 | -132.9 | -86.06 | -104.45 | 1.35 | 4.48 |
Minority Interest in Earnings | 64.54 | 85.15 | 62.9 | 39.64 | -0.46 | 0.01 |
Net Income | -45.25 | -47.75 | -23.16 | -64.81 | 0.88 | 4.5 |
Net Income to Common | -45.25 | -47.75 | -23.16 | -64.81 | 0.88 | 4.5 |
Net Income Growth | - | - | - | - | -80.38% | -55.25% |
Shares Outstanding (Basic) | 7 | 6 | 6 | 6 | 6 | 6 |
Shares Outstanding (Diluted) | 7 | 6 | 6 | 6 | 6 | 6 |
Shares Change (YoY) | 6.35% | - | - | - | - | - |
EPS (Basic) | -6.74 | -7.56 | -3.67 | -10.27 | 0.14 | 0.71 |
EPS (Diluted) | -6.74 | -7.56 | -3.67 | -10.27 | 0.14 | 0.71 |
EPS Growth | - | - | - | - | -80.38% | -55.21% |
Free Cash Flow | -90.94 | -91.02 | -7.21 | -293.17 | -119.02 | -152.22 |
Free Cash Flow Per Share | -13.55 | -14.42 | -1.14 | -46.45 | -18.86 | -24.12 |
Gross Margin | -36.66% | 21.67% | 91.27% | 84.21% | 91.86% | 90.76% |
Operating Margin | -614.20% | -441.66% | -32.58% | -80.69% | 24.78% | 27.47% |
Profit Margin | -366.44% | -243.18% | -23.82% | -103.26% | 0.88% | 4.47% |
Free Cash Flow Margin | -736.47% | -463.56% | -7.41% | -467.13% | -118.81% | -151.45% |
EBITDA | -42.42 | -42.57 | 13.29 | -23.94 | 37.99 | 40.12 |
EBITDA Margin | - | -216.78% | 13.67% | -38.14% | 37.92% | 39.92% |
D&A For EBITDA | 33.42 | 44.16 | 44.97 | 26.7 | 13.16 | 12.51 |
EBIT | -75.84 | -86.72 | -31.68 | -50.64 | 24.83 | 27.61 |
EBIT Margin | - | - | -32.58% | -80.69% | 24.78% | 27.47% |
Effective Tax Rate | - | - | - | - | 41.03% | 23.91% |
Revenue as Reported | 13.06 | 20.74 | 98.29 | 69.63 | 101.11 | 100.73 |
Advertising Expenses | - | - | - | - | 0.03 | 0.12 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.